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Background. Concurrent chemoradiation (CChRT) is recommended as the evidence-based approach for the management of
patients (p) with locally advanced stage III NSCLC and a good performance status, although a clearly superior regimen has
not been identiﬁed. The aim of our study was to evaluate the effectiveness and toxicities of CChRT with bi-weekly docetaxel (D)
and cisplatin (C) and thoracic radiotherapy, after one cycle D–C induction chemotherapy.
Methods. Between May 2009 and July 2012, 50 chemo-naive p with histologically conﬁrmed inoperable locally advanced NSCLC,
stage IIIAN2/IIIB (no pleural T4) and adequate lung function (FEV1>1.1, V20<25%) were included in a phase II study was based
on one cycle of D 75mg/m2 on day 1 and C 40mg/m2 days 1–2 followed at 21 days by CChRT with bi-weekly D 40mg/m2 and
C 40mg/m2 for four courses, during conformal thoracic radiotherapy (66Gy, 180 cGy/day). The primary objective was overall
survival (OS); secondary objectives were progression free survival (PFS), response rate (RR) and toxicity. Median follow-up: 14.5
months.
Results. The p characteristics were: mean age 59.1 years (34–75); male/female 44/6; ECOG PS 0/1 in 16/34 p; squamous/adeno/large
cell carcinoma: 52%/34%/14%; stage IIIAN2 14 p (28%) and stage IIIB 36 p (72%). All p were evaluable for response and toxicity. RR:
4 CR, 36 PR (RR 80%; 95% CI: 69–91), 4 SD (8%) and 6 PD (12%). The median PFS was 13 months (95% CI: 8–18) and median OS was 19
months (95% CI: 14–24). The PFS and OS at 1/2 years were 52%/30% and 79%/40% respectively. A total of 50 cycles of D–C induction
chemotherapy were given; main toxicities (NCI-CTC 3.0) per p Grade (g) 1–2/3–4 (%) were as follows: neutropenia 2/16; anemia
12/0; nausea/vomiting 28/2; diarrhea 22/4; there were three episodes of hospitalization: febrile neutropenia, 2 p and g3 diarrhea,
1 p. Main toxicities per p in CChRT (D-C doses: 192, 3.8 per p; mean doses RT: 64.6Gys) were g1–2/3 (%): neutropenia 28/6; anemia
60/0; nausea/vomiting 20/0; fatigue 40/4; esophagitis 52/4 and pneumonitis 34/0; there were four episodes of hospitalization:
febrile neutropenia, 2 p and g3 esophagitis, 2 p.
Conclusions. CChRT with bi-weekly docetaxel and cisplatin and thoracic radiotherapy is a feasible treatment option for inoperable
locally advanced stage III NSCLC, showing good clinical efﬁcacy and tolerability with acceptable long-term survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.303
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Introduction. Selective nodal irradiation (SNI) based on FDG-PET scan is associated with a low percentage of isolated nodal recurr-
ences (3%) in patients with limited disease small cell lung cancer (LD-SCLC). This proportion increases to 11% with CT scan-based
SNI and these are often located in the supraclavicular area.
Objective. To evaluate the contribution of PET scan to reduce isolated nodal failure in patients with LD-SCLC treated with SNI.
Methods and materials. 10 patients who received deﬁnitive chemoradiotherapy for LD-SCLC were retrospectively analysed. RT was
given to a dose of 45Gy twice-daily by fractions of 1,5 Gy concurrent with cisplatin or carboplatin and etoposide chemotherapy.
Results. FDG-PET was performed in 5 patients at the time of diagnosis. Differences were observed in the involved nodal stations
between the pretreatment FDG-PET and CT-scan in 2 patients. At a median follow-up of 25 months (range 12–55) the 3 year overall
survival was 44%. The median actuarial overall survival was 30 months. Of 10 patients, 2 developed an isolated nodal recurrence.
Those stations (contralateral hilar and contralateral supraclavicular, respectively) were not involved before treatment on basis
of CT-scan, and PET was not performed. In a patient without initial PET-scan, a nodal recurrence outside the treatment ﬁeld
combined with in-ﬁeld recurrence were observed. This nodal area (homolateral supraclavicular) were only detected in PET-scan.
In 5 patients, distant metastases (4 isolated and 1 combined with locoregional recurrence) were present at recurrence. Concurrent
treatment was well tolerated without oesophagitis or pneumonitis grade 3 or greater.
Conclusion. Higher rates of nodal recurrence were observed in radiation treatment plan based on CT-scan. In contrast, when
FDG-PET based SNI was used, we have not observed any recurrence. Our results are consistent with the literature. Therefore, we
believe that selective nodal irradiation might be reasonable only with FDG-PET implementation.
http://dx.doi.org/10.1016/j.rpor.2013.03.304
